TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90 is a pioneering biopharmaceutical company. The Company has recently gained a significant ‘asset’ with the addition of Dr. Yona Geffen from Gameda Cell as a consultant, a move that is set to bolster the Company’s product development.
Dr. Geffen expressed her excitement about joining NurExone at a crucial stage in their drug development cycle. She particularly commended the innovative work and unique science behind the ExoPTEN nano drug for spinal cord injury, a project she is eager to contribute to along the regulatory and clinical pathway.
Dr. Noa Avni, NurExone’s Director of Research and Development, emphasized the significance of Dr. Geffen’s expertise and experience, highlighting how they will be instrumental in the company’s progress in the biotech industry and the utilization of exosomes for regenerative medicine. The team is excited about her contributions and welcomes her warmly.
Dr. Yona Geffen joined Gamida Cell’s leadership team as vice president of research and development in December 2020, bringing over two decades of experience leading clinical and drug development in the biotechnology and pharmaceutical industry. Before joining Gamida Cell, Yona served in different positions, including vice president of research and development at Stem Cell Medicine, vice president of research and validation at Compugen, and several roles, including senior vice president, clinical development, chief operations officer and chief executive officer at Avraham Pharmaceuticals.
NRX produces substantive Press Releases weekly or less. More biologics don’t, as either they can’t provide a coherent picture or they just don’t care and are waiting to be bought out. The one-year chart bears this fact out, left. There are periods when the stock is a good trader, and quick profits can be made. A combination of dollar cost averaging with a portion earmarked to take advantage of these decent price spurts.
That theory may seem counterintuitive, but the quality and amount of great news –adding Dr. Geffen for example—are not fluff. What intrigues me is that NRX doesn’t act like a biologic but more like a commodity stock. If you class drugs and therapies as commodities, the theory makes sense.
NRX is worth owning for the above reasons. It is also a very solid proxy for the biopharmaceutical space.
It may just cure what ails your portfolio. (See how I did that?)
Posted on behalf of NurExone Biologic
Bob Beaty
For over 30 years, Bob Beaty has been explaining concepts and companies to the global investment community. One of the original writers for Jim Cramer’s Thestreet.com, he also wrote for AOL (Can/US), the Globe and Mail, and the Huffington Post. Over that period, he illuminated small-cap companies to investors with wit and pith but mostly opinion and facts. Investing should be fun. Pedantic, staid content is no fun.
Before embarking on his writing career, Bob had a successful international journey in the finance industry. He served as a broker, derivatives product manager, and a Director of London's Credit Suisse subsidiary. His career spanned across major financial hubs including Toronto, Vancouver, and the UK, giving him a unique global perspective. (He is still fondly remembering those English client lunches.)
Other than everything Groucho Marx and George Carlin ever said, Bob lives by a simple credo;
‘Never do anything the person standing in front of you can't understand.’ Hunter S. Thompson.
Let’s go.
